Pharma giant Wyeth announced plans yesterday to eliminate research in half of its disease research areas. The company has not yet said what, if any, jobs will be cut in the process. A handful of other linkurl:pharmaceutical companies;http://www.the-scientist.com/2007/2/1/42/1/ have recently narrowed their research focus in response to linkurl:sluggish sales and the growing cost;http://www.the-scientist.com/article/display/54972/ of drug development. Wyeth in particular has suffered from the loss of revenue from its blockbuster ulcer medication, pantoprazole (Protonix), which became available in generic form last year. The company has not disclosed how many jobs will be cut, but its R&D program will be scaled back to 27 therapeutic areas from 55, with a focus on oncology, inflammation, and vaccines, among others. The WSJ Health Blog linkurl:reported;http://blogs.wsj.com/health/2008/10/28/wyeth-joins-rd-restructuring-parade/#more-3534 that Wyeth will keep the overall number of scientific jobs, but that some scientists will be cut because their skills don't translate to other research areas. In addition, teams...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!